safety of glp-1 receptor agonists The New Unraveling the safety profile of

Description

What are the long-term risks associated with glucagon-like peptide-1 (GLP-1) receptor agonist therapy?

Given the established clinical use of GLP-1RAs for the treatment of T2DM, preclinical and clinical research was centered largely around DR, which suggested the neuropathologic protective effects of GLP-1 are due to downregulation of NF-B, proinflammatory cytokines such as TNF-alpha and IL-1beta, and VEGF

Tan X, Pan X, Wu X, Zheng S, Chen Y, Liu D, et al

A new entrant was about to change the landscape again: semaglutide , a molecule even more potent at weight reduction and glycemic control, which would further elevate the GLP-1 class including heading into oral dosage forms and unprecedented trial results

Then you'll see your doctor at regular intervals so they can monitor you for side effects, track your progress, and monitor for any potential adverse effects